TC BioPharm
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 41
- Market Cap
- -
- Introduction
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- TC Biopharm
- Target Recruit Count
- 69
- Registration Number
- NCT06463327
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- TC Biopharm
- Target Recruit Count
- 53
- Registration Number
- NCT05358808
- Locations
- 🇬🇧
Bristol and Weston NHS foundation trust, Bristol, United Kingdom
🇬🇧Cardiff and Vale University LHB, Cardiff, United Kingdom
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- TC Biopharm
- Registration Number
- NCT04834128
- Locations
- 🇬🇧
Royal Victoria Infirmary, Newcastle, United Kingdom
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- TC Biopharm
- Target Recruit Count
- 10
- Registration Number
- NCT03790072
- Locations
- 🇨🇿
UHKT (Ustav hematologie a krevni transfuze), Praha, Czechia
ImmuniCell® in Patients With Advanced Cancers
- Conditions
- Malignant MelanomaNon-small Cell Lung CancerRenal Cell Cancer
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- TC Biopharm
- Target Recruit Count
- 8
- Registration Number
- NCT02459067
- Locations
- 🇬🇧
Velindre Cancer Centre and University Hospital of Wales, Cardiff, United Kingdom
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
News
TC Biopharm Leads Gamma Delta T Cell Therapy Development with Over 25 Clinical Programs Worldwide
TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally.
Allogeneic Cell Therapies Emerge as Next-Generation Cancer Treatment to Address Manufacturing and Cost Challenges
Allogeneic "off-the-shelf" cell therapies are being developed to overcome the complex manufacturing and supply chain limitations of current autologous CAR-T treatments, which require 9-14 days to produce individualized therapies.
TC BioPharm to Acquire Ophthalmic Pharmaceutical Company with FDA-Approved Glaucoma Treatment
TC BioPharm has signed a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved once-daily eye drop for glaucoma and ocular hypertension.
CareDx and TC BioPharm Partner to Enhance AlloCell Monitoring in AML Trial
CareDx partners with TC BioPharm to perform pharmacokinetic analysis in the ACHIEVE clinical trial using its AlloCell solution.
TC BioPharm's TCB008 Shows Promise in Phase 2b ACHIEVE Trial for Acute Myeloid Leukemia
TC BioPharm's ACHIEVE Phase 2b trial evaluates TCB008 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML).
TC BioPharm Expands ACHIEVE AML Trial with New Site at Guys and St. Thomas Hospital
TC BioPharm has opened a new clinical trial site at Guys and St. Thomas Hospital in London to accelerate enrollment in the ACHIEVE study.
TC BioPharm's TCB008 Shows Promising Safety Profile in ACHIEVE Trial for AML/MDS
TC BioPharm announced the first patient completed the full dosing regimen of TCB008 in the ACHIEVE Phase 2b trial without drug-related adverse events.
TC BioPharm to Explore Gamma Delta T-Cell Therapy TCB008 for Mpox Treatment
TC BioPharm is initiating preclinical studies for TCB008, an unmodified cell therapy, to treat Mpox, leveraging the role of gamma delta T-cells in viral infections.